MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs

Silvia Maifrede; Esteban Martinez; Margaret Nieborowska-Skorska; Daniela Di Marcantonio; Michael Hulse; Bac Viet Le; Huaqing Zhao; Katarzyna Piwocka; Italo Tempera; Stephen M Sykes; Tomasz Skorski

doi:10.1182/bloodadvances.2017006247

MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs

Blood Adv. 2017 Aug 9;1(19):1467-1472. doi: 10.1182/bloodadvances.2017006247. eCollection 2017 Aug 22.

Authors

Affiliations

¹ Department of Microbiology and Immunology, Temple University Lewis Katz School of Medicine, Philadelphia, PA.
² Blood Cell Development and Function Program, Research Institute of Fox Chase Cancer Center, Philadelphia, PA.
³ Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA.
⁴ Laboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland; and.
⁵ Department of Clinical Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, PA.

Abstract

PARP1 is required for the maintenance of MLL-AF9 leukemias.PARP1 inhibitors enhance the therapeutic effect of cytotoxic drugs against MLL-AF9 leukemias.

Abstract

Grants and funding